These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1456745)

  • 1. Carnitine acetyltransferase activity in the human brain and its microvessels is decreased in Alzheimer's disease.
    Kalaria RN; Harik SI
    Ann Neurol; 1992 Oct; 32(4):583-6. PubMed ID: 1456745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease: choline acetyltransferase activity in brain tissue from clinical and pathological subgroups.
    Bird TD; Stranahan S; Sumi SM; Raskind M
    Ann Neurol; 1983 Sep; 14(3):284-93. PubMed ID: 6227276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitric oxide synthase activity is elevated in brain microvessels in Alzheimer's disease.
    Dorheim MA; Tracey WR; Pollock JS; Grammas P
    Biochem Biophys Res Commun; 1994 Nov; 205(1):659-65. PubMed ID: 7528015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of choline acetyl transferase activity by l- and d-carnitine in brain areas of neonate rats.
    Ayala CA
    J Neurosci Res; 1995 Jun; 41(3):403-8. PubMed ID: 7563233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetyl-l-carnitine as a possible therapy for Alzheimer's disease.
    Pettegrew JW; McClure RJ
    Expert Rev Neurother; 2002 Sep; 2(5):647-54. PubMed ID: 19810980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Butyrylcholinesterase, ApoE and Alzheimer's disease in a population from the Canary Islands (Spain).
    Déniz-Naranjo MC; Muñoz-Fernández C; Alemany-Rodríguez MJ; del Carmen Pérez-Vieitez M; Aladro-Benito Y; Irurita-Latasa J; Sánchez-García F
    Neurosci Lett; 2007 Oct; 427(1):34-8. PubMed ID: 17923322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetyl-L-carnitine.
    Altern Med Rev; 1999 Dec; 4(6):438-41. PubMed ID: 10608918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetyl-L-carnitine and Alzheimer's disease: pharmacological considerations beyond the cholinergic sphere.
    Carta A; Calvani M; Bravi D; Bhuachalla SN
    Ann N Y Acad Sci; 1993 Sep; 695():324-6. PubMed ID: 8239306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques.
    Katzman R; Terry R; DeTeresa R; Brown T; Davies P; Fuld P; Renbing X; Peck A
    Ann Neurol; 1988 Feb; 23(2):138-44. PubMed ID: 2897823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced phospholipase D activity in brain tissue samples from Alzheimer's disease patients.
    Kanfer JN; Hattori H; Orihel D
    Ann Neurol; 1986 Aug; 20(2):265-7. PubMed ID: 3019230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease.
    Blass JP; Gibson GE
    Rev Neurol (Paris); 1991; 147(6-7):513-25. PubMed ID: 1962057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative therapy of Alzheimer's disease via supplementation with choline acetyltransferase.
    Fu AL; Li Q; Dong ZH; Huang SJ; Wang YX; Sun MJ
    Neurosci Lett; 2004 Sep; 368(3):258-62. PubMed ID: 15364407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carnitine acetyltransferase is not a cytosolic enzyme in rat heart and therefore cannot function in the energy-linked regulation of cardiac fatty acid oxidation.
    Abbas AS; Wu G; Schulz H
    J Mol Cell Cardiol; 1998 Jul; 30(7):1305-9. PubMed ID: 9710799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Physiological functions of carnitine and carnitine transporters in the central nervous system].
    Inazu M; Matsumiya T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Jun; 28(3):113-20. PubMed ID: 18646596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of kinesin light-chain 1 gene expression by acetyl-L-carnitine: therapeutic possibility in Alzheimer's disease.
    Traina G; Federighi G; Brunelli M
    Neurochem Int; 2008 Dec; 53(6-8):244-7. PubMed ID: 18761385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormalities of the glucose transporter at the blood-brain barrier and in brain in Alzheimer's disease.
    Kalaria RN; Harik SI
    Prog Clin Biol Res; 1989; 317():415-21. PubMed ID: 2602426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetyl-L-carnitine as a precursor of acetylcholine.
    White HL; Scates PW
    Neurochem Res; 1990 Jun; 15(6):597-601. PubMed ID: 2215852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neural correlates of verbal short-term memory in Alzheimer's disease: an fMRI study.
    Peters F; Collette F; Degueldre C; Sterpenich V; Majerus S; Salmon E
    Brain; 2009 Jul; 132(Pt 7):1833-46. PubMed ID: 19433442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain protein and alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease.
    Mastrogiacoma F; Lindsay JG; Bettendorff L; Rice J; Kish SJ
    Ann Neurol; 1996 May; 39(5):592-8. PubMed ID: 8619544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.